Myriad Genetics MYGN Share-Based Payment - Unrecognized Cost of Nonvested Awards

Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies

GeneDx HoldingsWGS

$0-100%

BillionToOne, Inc. BLLN

$85.2M—

Castle BiosciencesCSTL

$94.5M+6.5%

Guardant HealthGH

——

Other financials

Income statement

See full

Revenue$200.4M+2.3%

Gross profit$137.6M+2.5%

Operating income-$30.7M-5.9%

Net income-$34.1M-34,000%

EPS (diluted)-$0.36—

Balance sheet

See full

Cash & equivalents$126.0M+24.8%

Total debt$211.5M+34.2%

Total equity$337.4M-52.1%

Total assets$673.7M-33.0%

Cash flow

See full

Operating cash flow-$15.7M+3.7%

CapEx$18.8M+181%

Free cash flow-$19.7M+65.1%

Valuation

See full

Market cap$512.85M+13.1%

Enterprise value$598.35M+17.3%

P/S0.6×+0.1×

Profitability

See full

Gross margin70%0.0pp

Operating margin-46.9%-88.3pp

Net margin-48.2%-72.9pp

FCF margin-17%—

Returns & leverage

See full

Return on equity-76.7%-98.4pp

Debt / equity0.6×+0.4×

Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's share-based payment - unrecognized cost of nonvested awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Myriad Genetics's share-based payment - unrecognized cost of nonvested awards?: Myriad Genetics (MYGN) reported share-based payment - unrecognized cost of nonvested awards of $0 in Q1 2026.
What does share-based payment - unrecognized cost of nonvested awards mean?: This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.